|
Teva’s (TEVA) TREANDA Approved by US FDA
StreetInsider.com (subscription) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
|
FDA Approves Teva’s TREANDA(R) (bendamustine HCI) Injection, a New Liquid …
MarketWatch TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
|
Halozyme Therapeutics, Inc. (HALO): Bullish On Halozyme: Short-Term …
Seeking Alpha The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin’s lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it’s looking like … |
Management of Marginal Zone LymphomaCancer NetworkThere are several different treatment approaches for SMZL, including single-agent rituximab, splenectomy, and traditional chemotherapy. Tsimberidou et al evaluated rituximab with or without chemotherapy…
|
Biosimilar Opportunities in an Evolving Market – New Report Available
SBWire (press release) In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |
UNITEDHEALTH GROUP INC. : Collaborations, New Studies, and New Drug …4-traders (press release)Gilead also informed that along with this NDA, the Company submitted data that supports the use of idelalisib for patients with iNHL that is refractory (non…
|
Breakthrough status for GSK/ Genmab’s Arzerra
PMLiVE … to treatment with fludarabine and alemtuzumab since 2009, but sales have been modest – just £60m ($96m) last year for example – as the company has struggled to differentiate its product from Roche’s Rituxan/ MabThera (rituximab) in the marketplace. |
China Monoclonal Antibody Market Is Expected to Exceed CNY 10 Billion by 2017SBWire (press release)Among that, Roche (plus Genentech) was the leading monoclonal antibody enterprises, which possessed seven products sold in the market including Avastin, …
OncLiveUpdates in Hematology OncologyOncLiveBendamustine was approved in 2008 for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen as well …
|
Biosimilar Opportunities in an Evolving Market
WSLS In terms of revenue, six of the top ten pharmaceutical therapies are biological products, which have been targeted by biosimilar developers: Abbvie’s Humira (adalimumab), Roche’s MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab), … |